Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Zoetis Inc (ZTS) Adds Pershing Square’s William Doyle To Board

Zoetis Inc (NYSE:ZTS) has entered into an agreement with Bill Ackman’s Pershing Square to appoint William Doyle to the company’s board of directors, a new filing with the U.S. Securities and Exchange Commission showed.

Mr. Doyle is a member of Pershing Square’s Investment Team, and his appointment will expand the size of company’s board to ten from nine directors. According to the filing, Pershing Square is the largest shareholder of Zoetis Inc (NYSE:ZTS), in which the fund holds 41.82 million shares, representing 8.3% of common stock shares outstanding.

Bill Ackman in crowd

Pershing Square is a New York-based hedge fund founded and run by Bill Ackman. Mr. Ackman is a long term value investor, who takes advantage of short term downward moves in prices. He is particularly successful at special situations investments. Pershing Square had around $12 billion in assets under management in early 2014. The fund lost 1.1% in 2011 but gained 12.4% in 2012, 9.7% in 2013. Pershing Square has a very concentrated portfolio. As of the end of September 2014, the value of the fund’s equity portfolio totaled $13.4 billion. Allergan Inc. (NYSE:AGN), Canadian Pacific Railway Limited (USA) (NYSE:CP), and Air Products & Chemicals Inc. (NYSE:APD) were represented as the largest shareholders of Zoetis Inc (NYSE:ZTS) as of the end of September 2014.

Bill Ackman is the notorious investor. Last month, in an interview on Bloomberg Television, Mr. Ackman has discussed his investment strategy, as well as provided its opinion regarding oil prices decline and mentioned that he was considering investing in the UK retailer Tesco PLC (LON:TSCO), among other things. During his interview with Bloomberg TV’s Francine Lacqua and Guy Johnson, Mr. Ackman stated that the main target of Pershing Square’s investment strategy are high quality companies that run a predictable business model and are capable of generating free cash flow. Moreover, Pershig Square also prefers to invest in companies that are not exposed to commodity prices and have unique assets and long-term contracts, among other factors.

Mr. Ackman tried to acquire Allergan, Inc. (NYSE:AGN) jointly with Valeant Pharmaceuticals Intl Inc (NYSE:VRX). However, even though, after a pretty rough proxy fight, Allergan was sold to Actavis plc (NYSE:ACT) instead of Valeant. In November, Mr. Ackman’s Pershing Square disclosed taking a massive position in Zoetis Inc (NYSE:ZTS). At that time, we made an assumption that Pershing Square might pursue Zoetis Inc (NYSE:ZTS) into selling itself to Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.